Karuna Therapeutics, Inc.

$329.83+0.03%(+$0.09)
TickerSpark Score
56/100
Mixed
50
Valuation
35
Profitability
10
Growth
84
Health
100
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KRTX research report →

52-Week Range100% of range
Low $158.38
Current $329.83
High $329.99

Companywww.karunatx.com

Karuna Therapeutics, Inc. , a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis.

CEO
William Meury
IPO
2019
Employees
339
HQ
Boston, MA, US

Price Chart

+72.12% · this period
$329.83$245.42$161.01Mar 17Sep 18Mar 18

Valuation

Market Cap
$12.60B
P/E
-28.11
P/S
19264.95
P/B
9.72
EV/EBITDA
-25.21
Div Yield
0.00%

Profitability

Gross Margin
-160.09%
Op Margin
-75653.98%
Net Margin
-66311.93%
ROE
-36.44%
ROIC
-38.93%

Growth & Income

Revenue
$654.00K · -93.85%
Net Income
$-433,680,000 · -56.94%
EPS
$-11.73 · -34.21%
Op Income
$-494,777,000
FCF YoY
-69.81%

Performance & Tape

52W High
$329.99
52W Low
$158.38
50D MA
$317.38
200D MA
$228.31
Beta
1.15
Avg Volume
971.83K

Get TickerSpark's AI analysis on KRTX

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
Mar 18, 24Wheadon David E.sell25,000
Mar 18, 24Wheadon David E.sell8,500
Mar 18, 24Wheadon David E.sell990
Mar 18, 24Wheadon David E.sell5,000
Mar 18, 24Wheadon David E.sell1,904
Mar 18, 24Torres Denicesell990
Mar 18, 24Torres Denicesell5,000
Mar 18, 24Torres Denicesell1,904
Mar 18, 24Torres Denicesell8,500
Mar 18, 24Torres Denicesell25,000

Our KRTX Coverage

We haven't published any research on KRTX yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate KRTX Report →

Similar Companies